Related Experiment Video
Updated: May 16, 2025
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
1.6K
Anticancer drug therapy for anaplastic thyroid cancer
European Thyroid Journal
|March 31, 2025
Summary
Anaplastic thyroid cancer, a rare and aggressive disease, has limited treatment options. Novel therapies like BRAF/MEK inhibitors and immune checkpoint inhibitors show promise, gradually improving patient prognosis.
Area of Science:
- Oncology
- Endocrinology
- Rare Cancers
Background:
- Anaplastic thyroid cancer (ATC) is exceptionally rare, comprising 1-2% of all thyroid cancers.
- It is highly aggressive, with a near 100% disease-specific mortality rate and dismal prognosis.
- The rarity of ATC limits prospective clinical trial data and the establishment of standard chemotherapeutic options for unresectable or metastatic disease.
Purpose of the Study:
- To review the current therapeutic landscape for anaplastic thyroid cancer.
- To highlight emerging novel treatment strategies and their impact on prognosis.
- To emphasize the need for international collaboration in rare cancer research.
Main Methods:
- Literature review of recent advancements in anaplastic thyroid cancer treatment.
- Analysis of clinical trial outcomes for targeted therapies and immunotherapies.
- Discussion of challenges and future directions in rare thyroid cancer research.
Main Results:
- Combination therapy with BRAF and MEK inhibitors demonstrates encouraging efficacy in BRAF V600E-mutated ATC.
- Immune checkpoint inhibitors are showing promising results in clinical investigations.
- These novel treatments suggest a gradual improvement in the prognosis for anaplastic thyroid cancer.
Conclusions:
- Despite challenges, therapeutic advances are improving anaplastic thyroid cancer outcomes.
- Targeted therapies (BRAF/MEK inhibitors) and immunotherapies represent significant progress.
- Further development necessitates robust infrastructure for international collaborative studies in rare malignancies.
Related Concept Videos
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:27Tumor Immunotherapy
432
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
432
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K